Overview

Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC

Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The investigators propose to study the efficacy and safety of the combination of Docetaxel plus Bevacizumab in a Phase II trial of elderly subjects with non-small cell lung cancer
Phase:
Phase 2
Details
Lead Sponsor:
Hellenic Oncology Research Group
Treatments:
Bevacizumab
Docetaxel